Enveric Biosciences (NASDAQ:ENVB) Stock Price Up 4.2% – What’s Next?

Enveric Biosciences, Inc. (NASDAQ:ENVB)’s share price rose 4.2% during trading on Monday . The stock traded as high as $1.5378 and last traded at $1.48. 104,186 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 101,824 shares. The stock had previously closed at $1.42.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen raised shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Enveric Biosciences presently has an average rating of “Sell”.

Enveric Biosciences Price Performance

The company has a market cap of $6.60 million, a P/E ratio of -0.12 and a beta of 1.11. The company has a 50 day moving average of $1.42 and a 200-day moving average of $1.93.

Enveric Biosciences (NASDAQ:ENVB) last announced its earnings results on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.